Holen Sie sich die Stockscreener-App
184.38
1.86%
-3.50
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$187.88
Offen:
$186.65
24-Stunden-Volumen:
723.30K
Relative Volume:
0.59
Marktkapitalisierung:
$27.06B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
20.94
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
+3.96%
1M Leistung:
+0.24%
6M Leistung:
+23.01%
1J Leistung:
+54.28%
1-Tages-Spanne:
$183.17
$186.65
1-Wochen-Bereich:
$178.72
$192.75
52-Wochen-Spanne:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
184.38 | 27.06B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Buyout Bet On Felzartamab: A Hidden Blockbuster In The Making? - Smartkarma
The Goldman Sachs Group Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $21.83 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Should Biogen’s (BIIB) Full Global Control of Felzartamab Require Action From Investors? - simplywall.st
BofA raises Biogen stock price target to $200 on base business - Investing.com
Goldman Sachs Adjusts Price Target on Biogen to $238 From $231, Maintains Buy Rating - marketscreener.com
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise? - TradingView
Wolfe Research Has Bearish Forecast for Biogen Q2 Earnings - MarketBeat
Postpartum Depression Market is projected to Hit USD 93.6 - openPR.com
Biogen secures FDA nod for higher dose of SMA drug Spinraza - MSN
Analysts estimate Biogen Inc. (BIIB) to report a decline in earnings: What to look out for - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention - simplywall.st
JPMorgan Adjusts Price Target on Biogen to $185 From $175, Maintains Neutral Rating - marketscreener.com
Jim Cramer Says “I Got to Reopen the File on Biogen” - Insider Monkey
BIIB (Biogen Inc.) exceeds Q4 2025 earnings forecasts, shares tick higher on steady year over year revenue growth.Joint Venture - Cổng thông tin điện tử tỉnh Lào Cai
Earnings preview: Biogen Inc. (BIIB) Q1 earnings expected to decline - MSN
Biogen Loses Multiple Sclerosis Treatment Patent On Appeal - Law360
Biogen strengthens global pipeline with $100m TJ biopharma partnership - BioXconomy
BIOGEN LT-Debt-to-Total-Asset: 0.22 | Fairly Valued - GuruFocus
BIIB (Biogen) Fixed Maturity Investment - GuruFocus
Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027 - Proactive financial news
Biogen Stock Analysis: Recent Gains Mask Long-Term Financial WeaknessNews and Statistics - IndexBox
BIOGEN Tax Provision: $-264 Mil | Fairly Valued - GuruFocus
BIOGEN Debt-to-Revenue: 0.72 | Fairly Valued - GuruFocus
BIIB (Biogen) DeferredTaxAndRevenue : $0 Mil (As of Dec. 2025) - GuruFocus
BIOGEN Total Equity: $18,257 Mil | Fairly Valued - GuruFocus
UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts - Investing.com Canada
Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says - marketscreener.com
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade? - 24/7 Wall St.
BIIB Upgraded by UBS -- Price Target Raised to $225 - GuruFocus
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline - Yahoo Finance
FY2026 Earnings Estimate for Biogen Issued By HSBC - MarketBeat
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More - Yahoo Finance
Biogen (BIIB) Projected to Post Earnings on Wednesday - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Sells 11,837 Shares of Biogen Inc. $BIIB - MarketBeat
UBS Upgrades Biogen to Buy From Neutral, Adjusts Price Target to $225 From $185 - marketscreener.com
Analyst recommendations: Albemarle, Biogen, Qualcomm, Twilio, Lyondellbasell… - marketscreener.com
TJ Biopharma enters into agreement with Biogen for Felzartamab assets in Greater China Region - BioSpectrum Asia
UBS upgrades Biogen stock rating on pipeline catalysts, raises target to $225 - Investing.com
UBS upgrades Biogen (BIIB) - MSN
Biogen Inc. (BIIB)Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares RallyViral Trade Signals - UBND thành phố Hải Phòng
Biogen Inc. (BIIB) – Strategic Portfolio Review Signals Near-Term Earnings HeadwindsDividend Yield - Xã Vĩnh Công
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen - Yahoo Finance
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma - BioPharma APAC
Biogen amasses full felzartamab rights with $850M TJ deal - BioWorld News
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up - TradingView
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance
Amyloid Setback: Future Possibilities For The Treatment Of Alzheimer's Disease - Seeking Alpha
Biogen gets worldwide development and commercialization rights to felzartamab - The Pharma Letter
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
2.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):